WO2014023288A1 - Verfahren zur einbringung biologisch aktiver substanzen ins gehirn - Google Patents
Verfahren zur einbringung biologisch aktiver substanzen ins gehirn Download PDFInfo
- Publication number
- WO2014023288A1 WO2014023288A1 PCT/DE2013/000458 DE2013000458W WO2014023288A1 WO 2014023288 A1 WO2014023288 A1 WO 2014023288A1 DE 2013000458 W DE2013000458 W DE 2013000458W WO 2014023288 A1 WO2014023288 A1 WO 2014023288A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- active substances
- nasal
- substances
- brain
- dopamine
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 34
- 210000004556 brain Anatomy 0.000 title claims abstract description 33
- 239000013543 active substance Substances 0.000 title claims abstract description 29
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 31
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 14
- 210000003928 nasal cavity Anatomy 0.000 claims abstract description 12
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 125
- 229960003638 dopamine Drugs 0.000 claims description 61
- 239000000126 substance Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 16
- 210000003169 central nervous system Anatomy 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 206010039101 Rhinorrhoea Diseases 0.000 claims description 3
- 239000002207 metabolite Substances 0.000 claims description 3
- 208000010753 nasal discharge Diseases 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 239000002858 neurotransmitter agent Substances 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 claims 1
- 108010024976 Asparaginase Proteins 0.000 claims 1
- 108010081952 Galanin-Like Peptide Proteins 0.000 claims 1
- 102100031689 Galanin-like peptide Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 1
- 229960004373 acetylcholine Drugs 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- UVITTYOJFDLOGI-KEYYUXOJSA-N trimeperidine Chemical compound C=1C=CC=CC=1[C@]1(OC(=O)CC)C[C@H](C)N(C)C[C@H]1C UVITTYOJFDLOGI-KEYYUXOJSA-N 0.000 claims 1
- 229950009395 trimeperidine Drugs 0.000 claims 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004688 venlafaxine Drugs 0.000 claims 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 53
- 229960003878 haloperidol Drugs 0.000 description 27
- 241000700159 Rattus Species 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 21
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 18
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 18
- 229930064664 L-arginine Natural products 0.000 description 18
- 235000014852 L-arginine Nutrition 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 230000008925 spontaneous activity Effects 0.000 description 11
- 208000009132 Catalepsy Diseases 0.000 description 9
- 206010047853 Waxy flexibility Diseases 0.000 description 9
- 210000001577 neostriatum Anatomy 0.000 description 9
- 239000000284 extract Substances 0.000 description 8
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 8
- 229960002695 phenobarbital Drugs 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000037023 motor activity Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000003016 hypothalamus Anatomy 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229910052722 tritium Inorganic materials 0.000 description 4
- 238000010171 animal model Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000002267 hypothalamic effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000003176 neuroleptic agent Substances 0.000 description 2
- 230000000701 neuroleptic effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- YPJUNDFVDDCYIH-UHFFFAOYSA-N perfluorobutyric acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)F YPJUNDFVDDCYIH-UHFFFAOYSA-N 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960001149 dopamine hydrochloride Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000010254 physiological adaptation Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000004617 sleep duration Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Definitions
- the invention relates to the development of a medical-biological method for the direct delivery of synthetic and natural biologically active and medicinal substances from the nasal cavity to the brain due to the interaction of these substances and membrane-active products of free-radical nature and / or the sources of these products with nerve and vascular structures the nasal cavity.
- the environment represents a source of various biologically active molecules arriving in an organism with foodstuffs or from an air environment.
- the other important sources of biologically active molecules are the internal sources of the organism, such as blood and interstitial fluid.
- the biologically active molecules from the external and internal milieu must penetrate the biological membranes, for example the membrane structures of the brain.
- biologically active molecules of the external and internal environment of the organism are useful and necessary for the normal functioning of organs and tissues, including the brain.
- the biologically active molecules include, in particular, the majority of drugs and many biochemical compounds - the products of metabolism that form in the organism in the metabolic processes.
- the authors see an important element of the successful solution of the problem in the presence in the pharmaceutical formula of cytokines or their sources.
- the method used by the authors represents only one possible route for nasal delivery of the drugs into the peripheral circulation and / or the brain and a means of immunization, and can only serve as a pharmacological and technological platform for further improving the nasal delivery of the drugs to serve for the treatment of brain diseases.
- the simultaneous detection at the wavelengths of 254 nm and 220 nm were carried out on the Beckman spectrophotometer (model 165, Altex), the sample volume was 100 ⁇ .
- the fractions of brain extracts from each animal of the Experimental and control groups to which separate [ 3 H] -DA and [ 3 H] -DOPAC were added were quantitatively analyzed by liquid scintillation counter.
- Figure 1 shows the typical chromatograms of the extracted solution, the hypothalamic and striatum extracts containing dopamine and DOPAC.
- Fig. 1 The radioactivity of [ 3 H] -DA and [ 3 H] -DOPAC in chromatographic extract fractions of rat brain hypothalamus and striatum.
- Rat catalepsy was developed by single intraperitoneal (ip) administration of the haloperidol ("ratiopharm") at the dose of 0.25 mg / kg. The catalepsy state and absence of response to external stimuli was determined as an 85% decrease in spontaneous motor activity. Thereafter, the animals of the three secreted rat group was administered 2 nasal nasal administration of the solutions of 10 -2 M dopamine, 0 "5 M H2O2 or mixture DA + H 2 O. The volume of the administered solutions was 50 ⁇ in each nose running The single dose of dopamine administered was 0.8 mg / kg, the dose of H 2 O 2 was 34 ng / animal, and the open field test was used to assess the spontaneous activity of the rats.
- haloperidol in the physiological experiments has significantly suppressed spontaneous activity of the rats.
- the latent period of catalepsy development after ip introduction of the haloperidol was 9.4 [8.9; 9.8] minutes; the catalepsy time was 57.1 [54.8; 59.4].
- the nasal initiation of the DA + H 2 0 2 mixture elicited significant recovery of spontaneous motor activity within 90 s.
- the separate introduction in the control animals of the isotonic water solutions of dopamine or H 2 0 2 did not restore the motor activity of the animals throughout the period of catalepsy (Fig. 2).
- the invention has for its object to provide a method which overcomes the disadvantages of the prior art and the biological and pharmaceutical active substances in the form of drugs after nasal administration by temporal, quantitative and in intended order of success directly into the brain effectively and be introduced advantageous.
- the criterion of evaluation the change of motor spontaneous activity as the sum of the movements of rats in different groups of animals in the test "open field".
- mice control group: “intact control” (group I), “haloperidol ip” (group II), “haloperidol ip + dopamine” (group III) and “haloperidol ip + H 2 O 2 " in different concentrations (groups IV and V).
- Experimental group “Haloperidol ip + dopamine + H 2 0 2 " in different concentrations (groups VI-IX), Tab. 2).
- V haloperidol ip + L-arginine (10 "& M), nasal (n 5) 4.8 ⁇ 2.7 ** '
- the maximum effective concentration of L-Arginine in nasal discharge is 10 " 1 M, as in the higher concentrations, the side effects of L-arginine are possible.
- the physiological reaction of the receptors of the nasal cavity depends strongly on the duration of the stimulus. During continuous stimulation, a reduction in response is associated with physiological adaptation. This poses a significant problem because the receptor adaptation to the stimulus acting, for example caused by H 2 O 2 - or ⁇ ⁇ , greatly reduces the sensitivity of the receptors as well as the dependent biological response (FR Schmidt, G. Thews, 1983 Human Physiology, Springer-Verlag, Berlin-Heidelberg-New York).
- This adaptation can reduce a therapeutic efficiency of drug substances.
- a method for maintaining the sensitivity of nasal receptors during the action of H 2 0 2 and » NO is not yet known.
- the method we develop consists of short-term intermittent (interrupted) action of neuroactive substances, for example H 2 O 2 or ⁇ , in a pharmaceutical composition with biologically and therapeutically active substances on the nasal cavity mucous membrane.
- the number of inserted sub-doses and the breaks between successively inserted sub-doses are substance-specific or application-specific and thereby from 1 to 5 sub-doses resp. from 10 to 60 seconds.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG11201505177XA SG11201505177XA (en) | 2012-08-05 | 2013-08-05 | Method for introducing biologically active substances into the brain |
EP13785814.8A EP2879668A1 (de) | 2012-08-05 | 2013-08-05 | Verfahren zur einbringung biologisch aktiver substanzen ins gehirn |
CN201380052365.2A CN104703590A (zh) | 2012-08-05 | 2013-08-05 | 用于将生物活性物质引入脑的方法 |
JP2015525738A JP2015527344A (ja) | 2012-08-05 | 2013-08-05 | 生物学的活性物質を脳に導入する方法 |
EA201590323A EA201590323A1 (ru) | 2012-08-05 | 2013-08-05 | Способ введения активных веществ в головной мозг |
US14/419,724 US20150328147A1 (en) | 2012-08-05 | 2013-08-05 | Method for introducing biologically active substances into the brain |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102012015248.5 | 2012-08-05 | ||
DE102012015248.5A DE102012015248A1 (de) | 2012-08-05 | 2012-08-05 | Verfahren zur Einbringung biologisch aktiver Substanzen ins Gehirn |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014023288A1 true WO2014023288A1 (de) | 2014-02-13 |
Family
ID=49517231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2013/000458 WO2014023288A1 (de) | 2012-08-05 | 2013-08-05 | Verfahren zur einbringung biologisch aktiver substanzen ins gehirn |
Country Status (8)
Country | Link |
---|---|
US (1) | US20150328147A1 (de) |
EP (1) | EP2879668A1 (de) |
JP (1) | JP2015527344A (de) |
CN (1) | CN104703590A (de) |
DE (1) | DE102012015248A1 (de) |
EA (1) | EA201590323A1 (de) |
SG (1) | SG11201505177XA (de) |
WO (1) | WO2014023288A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2846771A1 (de) * | 2012-05-09 | 2015-03-18 | BBU-VITA Corp. | Komposition für nasale anwendung |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991007947A1 (en) * | 1989-12-05 | 1991-06-13 | Ramsey Foundation | Neurologic agents for nasal administration to the brain |
US20020169102A1 (en) * | 2001-04-03 | 2002-11-14 | Frey William H. | Intranasal delivery of agents for regulating development of implanted cells in the CNS |
US20040028613A1 (en) * | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
WO2004037291A1 (de) * | 2002-10-17 | 2004-05-06 | Naum Goldstein | Pharmazeutisches mittel zur endonasalen applikation bei der behandlung von krankheiten und störungen des zentralen nervensystems |
US20050048002A1 (en) * | 2003-06-24 | 2005-03-03 | Barrett Rabinow | Method for delivering drugs to the brain |
US20080260699A1 (en) * | 2006-04-27 | 2008-10-23 | Toufan Parman | Adminstration of intact mammalian cells to the brain by the intranasal route |
US20090227550A1 (en) * | 2006-10-04 | 2009-09-10 | Claudia Mattern | Controlled release delivery system for nasal application of neurotransmitters |
WO2013167112A1 (de) * | 2012-05-09 | 2013-11-14 | Naum Goldstein | Komposition für nasale anwendung |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2846625A1 (de) | 1978-10-26 | 1980-05-08 | Basf Ag | M-anilidurethane |
DK1031347T3 (da) | 1999-01-27 | 2002-07-08 | Idea Ag | Transnasal transport/immunisering med meget tilpasselige bærere |
-
2012
- 2012-08-05 DE DE102012015248.5A patent/DE102012015248A1/de not_active Withdrawn
-
2013
- 2013-08-05 WO PCT/DE2013/000458 patent/WO2014023288A1/de active Application Filing
- 2013-08-05 EP EP13785814.8A patent/EP2879668A1/de not_active Withdrawn
- 2013-08-05 JP JP2015525738A patent/JP2015527344A/ja active Pending
- 2013-08-05 CN CN201380052365.2A patent/CN104703590A/zh active Pending
- 2013-08-05 SG SG11201505177XA patent/SG11201505177XA/en unknown
- 2013-08-05 EA EA201590323A patent/EA201590323A1/ru unknown
- 2013-08-05 US US14/419,724 patent/US20150328147A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991007947A1 (en) * | 1989-12-05 | 1991-06-13 | Ramsey Foundation | Neurologic agents for nasal administration to the brain |
US20020169102A1 (en) * | 2001-04-03 | 2002-11-14 | Frey William H. | Intranasal delivery of agents for regulating development of implanted cells in the CNS |
US20040028613A1 (en) * | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
WO2004037291A1 (de) * | 2002-10-17 | 2004-05-06 | Naum Goldstein | Pharmazeutisches mittel zur endonasalen applikation bei der behandlung von krankheiten und störungen des zentralen nervensystems |
US20050048002A1 (en) * | 2003-06-24 | 2005-03-03 | Barrett Rabinow | Method for delivering drugs to the brain |
US20080260699A1 (en) * | 2006-04-27 | 2008-10-23 | Toufan Parman | Adminstration of intact mammalian cells to the brain by the intranasal route |
US20090227550A1 (en) * | 2006-10-04 | 2009-09-10 | Claudia Mattern | Controlled release delivery system for nasal application of neurotransmitters |
WO2013167112A1 (de) * | 2012-05-09 | 2013-11-14 | Naum Goldstein | Komposition für nasale anwendung |
Non-Patent Citations (4)
Title |
---|
BUDDENBERG TIM E ET AL: "Behavioral actions of intranasal application of dopamine: Effects on forced swimming, elevated plus-maze and open field parameters", NEUROPSYCHOBIOLOGY, vol. 57, no. 1-2, June 2008 (2008-06-01), pages 70 - 79, XP009175342 * |
DHURIA SHYEILLA V ET AL: "Intranasal delivery to the central nervous system: mechanisms and experimental considerations.", JOURNAL OF PHARMACEUTICAL SCIENCES APR 2010, vol. 99, no. 4, April 2010 (2010-04-01), pages 1654 - 1673, XP055094068, ISSN: 1520-6017 * |
GOLDSTEIN N ET AL: "Blood-brain barrier unlocked", BIOCHEMISTRY (MOSCOW), KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 77, no. 5, 16 May 2012 (2012-05-16), pages 419 - 424, XP035057140, ISSN: 1608-3040, DOI: 10.1134/S000629791205001X * |
ILLUM L: "Is nose-to-brain transport of drugs in man a reality?", JOURNAL OF PHARMACY AND PHARMACOLOGY, JOHN WILEY & SONS LTD, LONDON; GB, vol. 56, no. 1, January 2004 (2004-01-01), pages 3 - 17, XP009071639, ISSN: 0022-3573, DOI: 10.1211/0022357022539 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2846771A1 (de) * | 2012-05-09 | 2015-03-18 | BBU-VITA Corp. | Komposition für nasale anwendung |
Also Published As
Publication number | Publication date |
---|---|
SG11201505177XA (en) | 2015-08-28 |
DE102012015248A1 (de) | 2014-02-06 |
EA201590323A1 (ru) | 2015-05-29 |
US20150328147A1 (en) | 2015-11-19 |
CN104703590A (zh) | 2015-06-10 |
EP2879668A1 (de) | 2015-06-10 |
JP2015527344A (ja) | 2015-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3335086C2 (de) | ||
AU2017250267A1 (en) | Compositions for topical application of compounds | |
Chen et al. | Activating mitochondrial regulator PGC-1α expression by astrocytic NGF is a therapeutic strategy for Huntington's disease | |
EP2679239A1 (de) | Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit | |
Kim et al. | Antidepressant effects of ginsenoside Rf on behavioral change in the glial degeneration model of depression by reversing glial loss | |
EP3461479B1 (de) | Nutrazeutische oder pharmazeutische zusammensetzungen und verwendungen zur erhaltung kognitiver funktionen | |
EP1283047B1 (de) | Methode zur herstellung einer bioaktiven substanz aus blutserum | |
JP6820323B2 (ja) | 組成物及びその使用 | |
EP2879668A1 (de) | Verfahren zur einbringung biologisch aktiver substanzen ins gehirn | |
DE69832165T2 (de) | Hgf zur behandlung von akutem nierenversagen | |
EP3352763B1 (de) | Substanz zur prophylaxe und behandlung von infektionen durch influenzaviren | |
WO1999047145A1 (de) | Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten | |
WO1996037198A1 (de) | Inhalative verwendung von antidepressiva zur behandlung von asthma | |
WO1994027625A1 (de) | Neuartiges anxiolytikum | |
EP1599211B1 (de) | Verwendung von isorhamnetin zur behandlung von depressiven verstimmungen und erkrankungen | |
RU2034558C1 (ru) | Вещество, обладающее радиозащитной активностью, и способ его получения | |
DE19909357A1 (de) | Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt | |
EP0869811B1 (de) | Immunologisch wirksame mistelextraktzubereitungen | |
Hasan et al. | Effect of oral activated charcoal on the pharmacokinetics of quinidine and quinine administered intravenously to rabbits | |
DE102005031363A1 (de) | Mittel mit Anti-Aging-Effekt | |
Lubkowska et al. | Distribution of fluoride in selected structures of the central nervous system in rats exposed to NaF and AICI 3 in drinking water. | |
DE3720232A1 (de) | Verfahren zur herstellung eines extraktes aus aloe-blaettern der pflanzengattung aloe capensis oder aloe arborescens | |
EP0241498B1 (de) | Schmerzstillendes und entzündungshemmendes arzneimittel auf pflanzlicher basis | |
EP1244442B1 (de) | Verfahren zur auffindung von nukleotidsyntheseinhibitoren mit weniger nebenwirkungen | |
WO2013167112A1 (de) | Komposition für nasale anwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13785814 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015525738 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1120130038889 Country of ref document: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2013785814 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013785814 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201590323 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14419724 Country of ref document: US |